ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SPRB Spruce Biosciences Inc

0.7535
0.0091 (1.22%)
May 06 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 351,553
Bid Price 0.7401
Ask Price 0.7519
News -
Day High 0.756

Low
0.6711

52 Week Range

High
5.95

Day Low 0.7251
Company Name Stock Ticker Symbol Market Type
Spruce Biosciences Inc SPRB NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0091 1.22% 0.7535 19:41:59
Open Price Low Price High Price Close Price Prev Close
0.75 0.7251 0.756 0.7542 0.7444
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,319 351,553 $ 0.7424972 $ 261,027 - 0.6711 - 5.95
Last Trade Time Type Quantity Stock Price Currency
19:52:08 20 $ 0.7518 USD

Spruce Biosciences Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
30.53M 40.71M - 10.09M -47.92M -1.18 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Spruce Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No SPRB Message Board. Create One! See More Posts on SPRB Message Board See More Message Board Posts

Historical SPRB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.70730.75720.690.7253944405,9170.04626.53%
1 Month0.8310.83980.67110.7216943562,915-0.0775-9.33%
3 Months4.415.950.67111.401,388,745-3.66-82.91%
6 Months1.105.950.67111.63786,139-0.3465-31.50%
1 Year2.315.950.67111.70446,939-1.56-67.38%
3 Years15.5116.20990.67113.35649,262-14.76-95.14%
5 Years17.0035.600.67113.73558,411-16.25-95.57%

Spruce Biosciences Description

Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).

Your Recent History

Delayed Upgrade Clock